26 results
8-K
EX-10.3
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
risk to be assessed and managed;
set the Company’s strategic aims, ensure that the necessary financial and human resources are in place for the Company
8-K
EX-10.4
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
and effective controls which enable risk to be assessed and managed;
set the Company’s strategic aims, ensure that the necessary financial and human … resources are in place for the Company to meet its objectives, and review management performance; and
set the Company’s values and standards and ensure
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
that the necessary financial and human resources are in place for the Company to meet its objectives, and review management performance; and
set the Company’s
424B3
2hoqg 166
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
s7z 5hfu4
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
s1fjx3u3
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.4
3bs6ai1sftkbpla6
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-10.1
77neqc kveeczl66
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
tnb588b27tidcaf0sxs7
6 Jul 18
Departure of Directors or Certain Officers
5:00pm